特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

間質性膀胱炎 (膀胱痛症候群) :パイプライン製品の分析

Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019

発行 Global Markets Direct 商品コード 213127
出版日 ページ情報 英文 88 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.61円で換算しております。
間質性膀胱炎 (膀胱痛症候群) :パイプライン製品の分析 Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2019
出版日: 2019年11月18日 ページ情報: 英文 88 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

間質性膀胱炎は、膀胱痛症候群とも呼ばれる慢性疾患で、膀胱圧、膀胱痛、骨盤痛など、軽度の不快感から激痛まで含まれます。膀胱容量の低下、性交痛、慢性骨盤痛、頻尿、尿意切迫感などの症状が見られます。危険因子は、年齢、性別、慢性疼痛性障害 (過敏性腸症候群、線維筋痛症など) です。治療には、非ステロイド性抗炎症薬、抗鬱薬、抗ヒスタミン薬などが含まれます。

当レポートでは、間質性膀胱炎 (膀胱痛症候群) に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

間質性膀胱炎 (膀胱痛症候群) の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

間質性膀胱炎 (膀胱痛症候群):企業で開発中の治療薬

間質性膀胱炎 (膀胱痛症候群):大学/機関で研究中の治療薬

間質性膀胱炎 (膀胱痛症候群):パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

間質性膀胱炎 (膀胱痛症候群):企業で開発中の製品

間質性膀胱炎 (膀胱痛症候群):大学/機関で研究中の製品

間質性膀胱炎 (膀胱痛症候群) の治療薬開発に従事している企業

  • Afferent Pharmaceuticals, Inc.
  • Allergan Plc
  • Aquinox Pharmaceuticals Inc.
  • アステラス製薬
  • Kytogenics Pharmaceuticals, Inc.
  • Lipella Pharmaceuticals, Inc.
  • MediPost Co., Ltd.
  • Qu Biologics Inc.
  • UCB S.A.
  • Urigen Pharmaceuticals, Inc.
  • UroGen Pharmaceuticals, Ltd.

間質性膀胱炎 (膀胱痛症候群):治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

間質性膀胱炎 (膀胱痛症候群):最近のパイプライン動向

間質性膀胱炎 (膀胱痛症候群):休止中のプロジェクト

間質性膀胱炎 (膀胱痛症候群):開発が中止された製品

間質性膀胱炎 (膀胱痛症候群):製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Alivio Therapeutics Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by GlycoMira Therapeutics Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Grunenthal GmbH, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Harrow Health Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Lipella Pharmaceuticals Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Mirae Cell Bio Co Ltd, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by UCB SA, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Urigen Pharmaceuticals Inc, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Pipeline by Xigen SA, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects, H2 2019
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Targets, H2 2019
  • Number of Products by Stage and Targets, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
目次
Product Code: GMDHC11476IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides an overview of the Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline landscape.

Interstitial cystitis also called painful bladder syndrome is a chronic condition in which person experience bladder pressure, bladder pain and sometimes pelvic pain, ranging from mild discomfort to severe pain. Symptoms include decreased bladder capacity, painful sexual intercourse, chronic pelvic pain and a persistent, urgent need to urinate. Risk factors include age, gender and chronic pain disorder, such as irritable bowel syndrome or fibromyalgia. Treatment includes non-steroidal anti-inflammatory drug, antidepressants and antihistamines.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Interstitial Cystitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical, Discovery and Unknown stages are 2, 4, 6, 1 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Interstitial Cystitis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Genito Urinary System And Sex Hormones)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Interstitial Cystitis (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Interstitial Cystitis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Overview
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Companies Involved in Therapeutics Development
    • Alivio Therapeutics Inc
    • GlycoMira Therapeutics Inc
    • Grunenthal GmbH
    • Harrow Health Inc
    • Kyorin Pharmaceutical Co Ltd
    • Lipella Pharmaceuticals Inc
    • Mirae Cell Bio Co Ltd
    • Pierre Fabre Pharmaceuticals Inc
    • UCB SA
    • Urigen Pharmaceuticals Inc
    • Xigen SA
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Drug Profiles
    • (heparin sodium + lidocaine hydrochloride) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • brimapitide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • certolizumab pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • F-16357 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GM-0111 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GRT-6010 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lidocaine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LP-08 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MAY-88 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-5937 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • onabotulinumtoxinA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pentosan polysulfate sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URG-801 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Dormant Projects
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Discontinued Products
  • Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 08, 2019: Mayfield Pharmaceuticals to Present update on MAY-88 drug candidate at the SVB Leerink New Treatments Focused on Women's Health Conference
      • Sep 12, 2018: U.S. Department of Defense awards $3.3 million grant to Alivio Therapeutics
      • Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis
      • May 18, 2015: Canadian Journal of Urology Study Highlights the Benefits of Heparin and Alkalinized Lidocaine Combination Formulation for the Relief of Interstitial Cystitis Symptoms
      • Jun 30, 2011: Urigen Provides Development Update For URG101
      • Aug 18, 2010: Urigen Reports Type C Meeting With FDA For URG101
      • Aug 11, 2010: Urigen Announces FDA Follow Up For URG101 Program For Treatment Of Interstitial Cystitis
      • Apr 23, 2010: Urigen Files Request For FDA Meeting
      • Dec 29, 2008: Urigen Amends Its Core UCSD License For URG101
      • Aug 20, 2008: Urigen Announces Issuance Of Key Patent To URG101 For Interstitial Cystitis
      • Apr 25, 2008: Urigen Announces US Patent Office Notice Of Allowance Of Claims For URG101
      • Apr 07, 2008: Urigen Announces Early Closure Of URG101 Phase II Clinical Trial based On Positive Interim Analysis Results
      • Dec 05, 2007: Urigen Pharmaceuticals and Hyaluron Contract Manufacturing, Inc. Enter Into Drug Development Agreement For URG101
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer